Evidence of active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 7 days prior to the initiation of study drug.
Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
COHORT 1: Has an active uncontrolled infection requiring systemic therapy (viral, bacterial or fungal); patients with infection under active treatment and controlled with antibiotics are eligible
COHORT 2: Has an active uncontrolled infection requiring systemic therapy (viral, bacterial or fungal); patients with infection under active treatment and controlled with antibiotics are eligible
Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
Active bacterial, viral, or fungal infection requiring systemic therapy.
Active bacterial, fungal, or viral infection requiring systemic treatment; patients who are receiving treatment for infections that are under control may be included in this study
Active, uncontrolled bacterial, viral, or fungal infections, within 7 days of study entry requiring systemic therapy.
Active, uncontrolled bacterial, viral, or fungal infections, within 7 days of study entry requiring systemic therapy.
Patients with active, uncontrolled bacterial, viral or fungal infection(s) requiring systemic therapy
Active, uncontrolled bacterial, viral, fungal, or other opportunistic infection requiring systemic therapy.
Subjects with active or uncontrolled bacterial, viral, or fungal infections requiring systemic therapy
Active systemic viral, bacterial or fungal infection requiring treatment
Subject exhibits evidence of uncontrolled systemic infection requiring therapy (viral, bacterial or fungal)
Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
Active bacterial or fungal infections requiring systemic treatment within 7 days of treatment
Active bacterial or viral infections requiring systemic therapy
Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
Active bacterial, viral, or fungal infections, requiring systemic therapy apart from anti-viral maintenance therapy for HIV.
Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
Active, uncontrolled bacterial, viral or fungal infection, requiring systemic therapy
Patient has active and uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
Active bacterial, viral, or fungal infection requiring systemic therapy or operative or radiological intervention.
Patients with active viral, bacterial or systemic fungal infection requiring treatment.
Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
Have active, bacterial, viral, or fungal infections, requiring systemic therapy
Patients with active or uncontrolled bacterial, viral, or fungal infections requiring systemic therapy
Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy.
Active systemic viral, bacterial or fungal infections requiring treatment.
Active, uncontrolled bacterial, viral, or fungal infection requiring systemic therapy
Subject has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy.
Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy.
Active viral, bacterial, or systemic fungal infection requiring parenteral treatment within four weeks of enrollment. Patients requiring any oral antiviral, fungal, or bacterial therapy must have completed treatment within one week of enrollment.
Active bacterial, viral, or fungal infection requiring systemic treatment at the time of study entry.
Active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 7 days of first study drug administration
Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
Presence of known active bacterial, fungal, or viral infection requiring systemic therapy
Participants with active bacterial, viral, or fungal infection requiring systemic treatment
Participants with active bacterial, viral, or fungal infection requiring systemic treatment within the last two months prior to registration
Active, uncontrolled bacterial, viral or fungal infection requiring systemic therapy.
Patient has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy.
Any active systemic infection (viral, fungal, or bacterial) requiring active parenteral antibiotic therapy within 4 weeks of study drug administration.
Any active systemic viral, bacterial, or fungal infection requiring IV treatment with antimicrobial therapy within 1 week prior to first dose
Patient has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy.
Active, uncontrolled bacterial, viral, or fungal infection requiring systemic therapy at time of screening.
Subject has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy.
Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
Evidence of uncontrolled, active infection, requiring systemic anti-bacterial, anti-viral or anti-fungal therapy ? 7 days prior to administration of study medication
Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
Active, uncontrolled bacterial, viral, or fungal infections requiring systemic therapy.
Patient has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
Patient has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
Subject has serious/active bacterial, viral or fungal infection requiring systemic treatment.
Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy.
History of active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 14 days
Active, uncontrolled bacterial, viral, or fungal infections, including urinary tract infection, within 7 days of study entry requiring systemic therapy
Active, uncontrolled bacterial, viral, or fungal infections requiring systemic therapy
Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
Patients with active or uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
Active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 7 days of first study drug administration
Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
Active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 7 days prior to the initiation of study drug.
